HL Financial Services LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.0% during the third quarter, Holdings Channel reports. The firm owned 79,831 shares of the biopharmaceutical company’s stock after buying an additional 3,813 shares during the period. HL Financial Services LLC’s holdings in Gilead Sciences were worth $6,316,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Van Hulzen Asset Management LLC boosted its position in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the last quarter. Gemmer Asset Management LLC boosted its position in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 175 shares during the last quarter. Joel Isaacson & Co. LLC boosted its position in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the last quarter. Roble Belko & Company Inc boosted its position in Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,035 shares during the last quarter. Finally, Pinkerton Retirement Specialists LLC boosted its position in Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 1,582 shares during the last quarter. Hedge funds and other institutional investors own 73.43% of the company’s stock.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 73.07 on Friday. Gilead Sciences, Inc. has a 12-month low of $70.83 and a 12-month high of $103.10. The firm has a market capitalization of $96.27 billion, a P/E ratio of 6.76 and a beta of 1.20. The stock’s 50 day moving average price is $73.96 and its 200-day moving average price is $77.97.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.87 by $0.12. The business earned $7.40 billion during the quarter, compared to analyst estimates of $7.47 billion. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The company’s quarterly revenue was down 9.6% compared to the same quarter last year. During the same quarter last year, the firm posted $3.22 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post $11.47 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th were given a $0.47 dividend. The ex-dividend date was Tuesday, December 13th. This represents a $1.88 annualized dividend and a yield of 2.57%. Gilead Sciences’s dividend payout ratio (DPR) is 17.44%.

COPYRIGHT VIOLATION NOTICE: “HL Financial Services LLC Has $6,316,000 Position in Gilead Sciences, Inc. (GILD)” was first published by Watch List News and is the propert of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international copyright legislation. The correct version of this piece of content can be accessed at http://www.watchlistnews.com/hl-financial-services-llc-has-6316000-position-in-gilead-sciences-inc-gild/1061355.html.

Several equities analysts have issued reports on the company. BMO Capital Markets reiterated a “market perform” rating and set a $88.00 target price on shares of Gilead Sciences in a research report on Friday. Goldman Sachs Group, Inc. (The) reiterated a “hold” rating on shares of Gilead Sciences in a research report on Friday. Stifel Nicolaus reiterated a “buy” rating and set a $100.00 target price on shares of Gilead Sciences in a research report on Wednesday. Cowen and Company reiterated a “buy” rating and set a $100.00 target price on shares of Gilead Sciences in a research report on Friday, January 6th. Finally, Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $86.88 target price on the stock in a research report on Thursday, January 5th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $96.33.

In related news, insider John C. Martin sold 73,337 shares of the firm’s stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $73.59, for a total value of $5,396,869.83. Following the completion of the transaction, the insider now owns 3,204,433 shares of the company’s stock, valued at approximately $235,814,224.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John W. Madigan sold 105,000 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the transaction, the director now directly owns 121,761 shares of the company’s stock, valued at approximately $9,115,028.46. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.